SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4602AL-1	SERIAL NO. 10/517,251
	APPLICANT HOGARTH et al.	
	FILING DATE December 7, 2004	GROUP ART <del>1635</del> 1632

## U.S. PATENT DOCUMENTS


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	AA						
	AB						
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
LDL	AD	03/101485	12-11-2003	WIPO				
LDL	AE	01/53312	07-26-2001	WIPO				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	AF	<del>European Search Report for EPO Application No. 03727011.3</del>
LDL	AG	"Functional Analysis of Human Fc-gamma-RII (CD32) Isoforms Expressed in B Lymphocytes", Van Den Herik-Oudijk, Ingrid E. et al., Journal of Immunology, vol. 152, no. 2, 1994, pp. 574-585
LDL	AH	"Phagosomal Maturation, Acidification, and Inhibition of Bacterial Growth in Nonphagocytic Cells Transfected with FC-gamma-RIIA Receptors", Downey G. P. et al., Journal of Biological Chemistry, American Society of Biochemistry and Molecular Biology, Inc., Birmingham, U.S., vol. 274, no. 40, October 1, 1999, pp. 28436-28444
LDL	AI	"Modulation of Immune Complex-Induced Inflammation in Vivo by the Coordinate Expression of Activation and Inhibitory FC Receptors", Clynes, R. et al., Journal of Experimental Medicine, Tokyo, Japan, vol. 189, no. 1, January 4, 1999, pp. 179-185

EXAMINER 	DATE CONSIDERED 4/03/06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

DT09 PCT/PTO 0 7 DEC 2004

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number <b>10/517251</b>	
				Filing Date June 6, 2003	
				First Named Inventor Phillip Mark Hogarth	
				Art Unit <b>1632</b>	
Examiner Name <b>Lieto</b>					
Sheet	1	of	1	Attorney Docket Number 4602AL-1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> ; Number <sup>3</sup> ; Kind Code <sup>4</sup> (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
<b>WOL</b>		PCT	- WO 96/08512	03/21/1996	Austin Research Institute Cancer and Antiinflammatory Syndicate No.1		
<b>WOL</b>		PCT	- WO 95/28959	11/02/1995	Sloan-Kettering Institute for Cancer Research		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. <sup>1</sup>	
<b>WOL</b>		"The Role of Human Fc Receptor FcγRIIA in the Immune Clearance of Platelets: A Transgenic Mouse Model", McKenzie et al., The Journal Immunology, pp. 4311-4318
<b>WOL</b>		"Functional Consequences of the Interaction Between T-cell Antigen Receptors and FcγRs on T Cells", Kwack et al., Immunology Letters, 44 (1995) pp. 139-143, Elsevier Science B.V.

Examiner Signature <b>[Signature]</b>	Date Considered <b>4/3/06</b>
---------------------------------------	-------------------------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.